Although in the clinics, PARP inhibitors have been used to treat cancers with DSB repair defects, such as BRCA1 and BRCA2 defect cancers, the drug resistance to PARP inhibitors is now a major problem facing the clinic. The gene discussed is BRCA2; the disease is cancer.